HOME >> MEDICINE >> NEWS
Studies compare hysterectomy vs. other medical treatments for abnormal uterine bleeding

s. 2), and satisfaction with health (31 vs. 14). By the end of the two-year follow-up, 17 (53 percent) of the women in the medicine group had requested and received hysterectomy, and these women reported improvements in quality-of-life outcomes during the two years that were similar to those reported by women randomized to the hysterectomy group. Women who continued in the medical treatment also reported some improvements, with the result that most differences between randomized groups at the end of the study were no longer statistically significant in the intention-to-treat analysis."

"We have shown that hysterectomy results in substantial improvement in health-related quality of life within six months for women who have not responded to medroxyprogesterone. Persisting efforts at medical treatment can also produce benefits for many of these women throughout the ensuing two years although others who prolong medical treatment at this stage will decide within a year to have a hysterectomy," the authors conclude.

(JAMA 2004; 291:1447-1455. Available post-embargo at JAMA.com)

Editor's Note: This research was funded by a grant from the Agency for Healthcare Research and Quality.

FINNISH STUDY COMPARES INTRAUTERINE HORMONE-DELIVERY SYSTEM VS. HYSTERECTOMY

In a second study in the March 24/31 issue of JAMA, researchers from Finland compare outcomes, quality-of-life issues, and costs of the levonorgestrel-releasing intrauterine system (LNG-IUS) versus hysterectomy in the treatment of menorrhagia (abnormally heavy menstrual bleeding).

"The LNG-IUS is an intrauterine system that releases 20 [micrograms] of levonorgesterel every 24 hours over 5 years. The LNG-IUS was developed during the 1980s and licensed first for contraception in Finland in 1990," the authors provide as background information. They add that in many countries, the LNG-IUS is licensed both for contraception and trea
'"/>

Contact: Eve Harris
415-885-7277
JAMA and Archives Journals
23-Mar-2004


Page: 1 2 3 4

Related medicine news :

1. Studies underscore genetic involvement in nicotine addiction & aggressive hostility
2. Studies address issues of risk and survival in rapidly increasing GI cancers
3. Studies examine coffee drinking and risk of liver and colorectal cancers
4. Studies reveal physicians attitudes on end-of-life care
5. Studies from the November issue of The Archives of Dermatology, a theme issue on facial rejuvenation
6. Studies link obesity to increased frequency of heartburn symptoms; greater risk of esophageal cancer
7. Studies demonstrate positive data in treatment of hepatitis C
8. Studies examine risk factors and potential consequences associated with prehypertension
9. Studies show ACTOS(R) (pioglitazone HCl) has positive effects on various components of dyslipidemia
10. Studies identify risk factors for colon cancer
11. Studies indicate healthy eating may affect cancer development, improve digestive system

Post Your Comments:
(Date:11/27/2014)... Cambrionix Ltd today announced that it ranked number ... of the 50 fastest-growing technology companies in the UK. ... five years. Cambrionix Ltd grew 2989 percent during this ... region of Cambridgeshire and East and first in the sector ... is recognition of the hard work put in by our ...
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer from an embarrassing fact of life, and she ... musty a few minutes later, I decided that there ... longer periods," she said. , Easy to use and ... maintains freshness in a woman’s private areas throughout the ...
(Date:11/27/2014)... Dotinga HealthDay Reporter , WEDNESDAY, ... pre-wired to acquire a second language, new research suggests. But ... likely gain a brain boost, the small study finds. ... said study co-author Ping Li, co-director of the Center for ... even more interesting, Li said, that "the brain networks of ...
(Date:11/27/2014)... THURSDAY, Nov. 27, 2014 (HealthDay News) -- Thanksgiving meals ... eat a gluten-free diet, an expert says. Many ... potatoes and cranberry sauce -- are gluten-free, but "when ... may need to be considered," Dr. Anca Safta, director ... Wake Forest Baptist Medical Center in North Carolina, said ...
(Date:11/27/2014)... NC (PRWEB) November 27, 2014 ... 12 years in the Charlotte area providing audits, ... examination services to businesses of varying size across ... business owners to meet all of their accounting ... certification through the QuickBooks ProAdvisor Program. When asking ...
Breaking Medicine News(10 mins):Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2
(Date:11/26/2014)... Zynerba Pharmaceuticals , Inc., a specialty ... synthetic cannabinoid treatments, today announced that the company will ... 2014. The conference will be held December 2 to ... New York . Zynerba,s Chairman and CEO, ... Tuesday, December 2. To listen to a ...
(Date:11/26/2014)... JOSE, Calif. , Nov. 26, 2014 /PRNewswire/ ... technologies to produce novel therapies for infectious diseases, ... , M.D., an internationally recognized key opinion leader ... the Company,s scientific advisory board. Founder ... Ph.D., stated, "We believe Dr. Opal,s extensive experience ...
(Date:11/26/2014)... NEW YORK and ... the leading distributor of market intelligence, MarketResearch.com is pleased ... by IQ4I Research and Consultancy focusing on the active ... about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Ingredients Global Market – Forecast to 2020 ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
Cached News: